Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
- 1 June 2004
- journal article
- research article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 38 (6) , 389-407
- https://doi.org/10.1080/j.1440-1614.2004.01377.x
Abstract
Background: The Royal Australian and New Zealand College of Psychiatrists (RANZCP) is co-ordinating the development of clinical practice guidelines (CPGs) in psychiatry, funded under the National Mental Health Strategy (Australia) and the New Zealand Ministry of Health. Method: The CPG team reviewed the treatment outcome literature, consulted with practitioners and patients and conducted meta-analyses of outcome research. Treatment recommendations: Establish an effective therapeutic relationship; provide the patient with information about the condition, the rationale for treatment, the likelihood of a positive response and the expected timeframe; consider the patient's strengths, life stresses and supports. Treatment choice depends on the clinician's skills and the patient's circumstances and preferences, and should be guided but not determined by these guidelines. In moderately severe depression, all recognized antidepressants, cognitive behavioural therapy (CBT) and interpersonal psychotherapy (IPT) are equally effective; clinicians should consider treatment burdens as well as benefits, including side-effects and toxicity. In severe depression, antidepressant treatment should precede psychological therapy. For depression with psychosis, electroconvulsive therapy (ECT) or a tricyclic combined with an antipsychotic are equally helpful. Treatments for other subtypes are discussed. Caution is necessary in people on other medication or with medical conditions. If response to an adequate trial of a first-line treatment is poor, another evidence-based treatment should be used. Second opinions are useful. Depression has a high rate of recurrence and efforts to reduce this are crucial.Keywords
This publication has 188 references indexed in Scilit:
- Treating depression in patients with cardiovascular diseaseHarvard Review of Psychiatry, 1999
- Efficacy and Tolerability of St. John's Wort Extract LI 160 Versus Imipramine in Patients with Severe Depressive Episodes According to ICD-10Pharmacopsychiatry, 1997
- LI 160, an Extract of St. John's Wort, Versus Amitriptyline in Mildly to Moderately Depressed Outpatients - A Controlled 6-Week Clinical TrialPharmacopsychiatry, 1997
- Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patientsHuman Psychopharmacology: Clinical and Experimental, 1995
- Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical studyInternational Clinical Psychopharmacology, 1994
- Double-Blind Multicenter Study of Paroxetine and Amitriptyline in Depressed InpatientsPharmacopsychiatry, 1993
- A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholiaInternational Clinical Psychopharmacology, 1993
- Fluoxetine versus amitriptyline in the treatment of major depressionInternational Clinical Psychopharmacology, 1993
- A Comparison of Fluoxetine and Amitriptyline in the Treatment of Major DepressionInternational Clinical Psychopharmacology, 1991
- Effectiveness of two psychological treatments for inpatients with severe and chronic depressionsCognitive Therapy and Research, 1986